Purpose: This study aimed to evaluate the efficacy and safety of the treatment with Y-90-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL).Experimental Design: From December 2006 to October 2008, 55 high-risk elderly (age >= 60 years) untreated DLBCL patients were treated in seven Italian institutions with a short-course of chemotherapy consisting of four cycles of R-CHOP21 followed by Y-90-ibritumomab tiuxetan 6 to 10 weeks later.Results: Of the 55 patients, 48 underwent radioimmunotherapy. The overall response rate to the entire treatment regimen was 80%, including 73% complete remissions and 7% partial remissions. Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after Y-90-ibritumomab tiuxetan administration. With a median follow-up of 18 months, the 2-year progression-free survival was estimated to be 85%, with a 2-year overall survival of 86%. Y-90-ibritumomab tiuxetan toxicity consisted of grade 3 to 4 hematologic toxicity in 28 of 48 patients, mainly neutropenia (23 patients) and thrombocytopenia (15 patients). Red cells and/or platelets transfusions were given to three patients.Conclusion: This study evaluated the feasibility, efficacy, and safety of a short-course R-CHOP21 regimen followed by Y-90-ibritumomab tiuxetan in high-risk elderly DLBCL patients. Clin Cancer Res; 16(15); 3998-4004. (C) 2010 AACR.

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients / Zinzani, Pier Luigi; Rossi, Giuseppe; Franceschetti, Silvia; Botto, Barbara; Di Rocco, Alice; Cabras, Maria Giuseppina; Petti, Maria Concetta; Stefoni, Vittorio; Broccoli, Alessandro; Fanti, Stefano; Pellegrini, Cinzia; Montini, Gian Carlo; Gandolfi, Letizia; Derenzini, Enrico; Argnani, Lisa; Fina, Mariapaola; Tucci, Alessandra; Bottelli, Chiara; Pileri, Stefano; Baccarani, Michele. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 16:15(2010), pp. 3998-4004-4004. [10.1158/1078-0432.CCR-10-0162]

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients

Di Rocco, Alice;Petti, Maria Concetta;
2010

Abstract

Purpose: This study aimed to evaluate the efficacy and safety of the treatment with Y-90-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL).Experimental Design: From December 2006 to October 2008, 55 high-risk elderly (age >= 60 years) untreated DLBCL patients were treated in seven Italian institutions with a short-course of chemotherapy consisting of four cycles of R-CHOP21 followed by Y-90-ibritumomab tiuxetan 6 to 10 weeks later.Results: Of the 55 patients, 48 underwent radioimmunotherapy. The overall response rate to the entire treatment regimen was 80%, including 73% complete remissions and 7% partial remissions. Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after Y-90-ibritumomab tiuxetan administration. With a median follow-up of 18 months, the 2-year progression-free survival was estimated to be 85%, with a 2-year overall survival of 86%. Y-90-ibritumomab tiuxetan toxicity consisted of grade 3 to 4 hematologic toxicity in 28 of 48 patients, mainly neutropenia (23 patients) and thrombocytopenia (15 patients). Red cells and/or platelets transfusions were given to three patients.Conclusion: This study evaluated the feasibility, efficacy, and safety of a short-course R-CHOP21 regimen followed by Y-90-ibritumomab tiuxetan in high-risk elderly DLBCL patients. Clin Cancer Res; 16(15); 3998-4004. (C) 2010 AACR.
File allegati a questo prodotto
File Dimensione Formato  
Zinzani_Phase II Trial_2010.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 228.09 kB
Formato Adobe PDF
228.09 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1275107
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 50
  • ???jsp.display-item.citation.isi??? 44
social impact